Evogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases

Reuters

Feb 11

Evogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases

Evogene Ltd. has announced a collaboration with Systasy Bioscience GmbH and LMU University Hospital Munich to develop novel therapies for neutrophil-derived inflammatory diseases, such as inflammatory bowel disease $(IBD)$. Supported by a pan-European EUREKA grant and involving the Weizmann Institute of Science, the partnership will combine Evogene’s AI-driven ChemPass AI™ platform for small molecule drug discovery, Systasy’s DNA barcoding technology for high-throughput pathway profiling, and LMU’s expertise in stem cell biology and precision diagnostics. The consortium aims to accelerate drug discovery and advance innovative therapies with significant clinical and commercial potential.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN85734) on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610303619"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610303619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610303619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610303619","market":"nz","top_or_hot":-1,"title":"Evogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVGN\">Evogene Ltd.</a> has announced a collaboration with Systasy Bioscience GmbH and LMU University Hospital Munich to develop novel therapies for neutrophil-derived inflammatory diseases, such as inflammatory bowel disease <a href=\"https://laohu8.com/S/IBD\">$(IBD)$</a>. Supported by a pan-European EUREKA grant and involving the Weizmann Institute of Science, the partnership will combine Evogene’s AI-driven ChemPass AI™ platform for small molecule drug discovery, Systasy’s DNA barcoding technology for high-throughput pathway profiling, and LMU’s expertise in stem cell biology and precision diagnostics. The consortium aims to accelerate drug discovery and advance innovative therapies with significant clinical and commercial potential.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN85734) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVGN\">Evogene Ltd.</a> has announced a collaboration with Systasy Bioscience GmbH and LMU University Hospital Munich to develop novel therapies for neutrophil-derived inflammatory diseases, such as inflammatory bowel disease <a href=\"https://laohu8.com/S/IBD\">$(IBD)$</a>. Supported by a pan-European EUREKA grant and involving the Weizmann Institute of Science, the partnership will combine Evogene’s AI-driven ChemPass AI™ platform for small molecule drug discovery, Systasy’s DNA barcoding technology for high-throughput pathway profiling, and LMU’s expertise in stem cell biology and precision diagnostics. The consortium aims to accelerate drug discovery and advance innovative therapies with significant clinical and commercial potential.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN85734) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL6zFQmM:1","article_id":"2610303619","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610303619","pubTimestamp":1770814901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases. Evogene Ltd. has announced a collaboration with Systasy Bioscience GmbH and LMU University Hospital Munich to develop novel therapies for neutrophil-derived inflammatory diseases, such as inflammatory bowel disease . Supported by a pan-European EUREKA grant and involving the Weizmann Institute of Science, the partnership will combine Evogene’s AI-driven ChemPass AI platform for small molecule drug discovery, Systasy’s DNA barcoding technology for high-throughput pathway profiling, and LMU’s expertise in stem cell biology and precision diagnostics. The consortium aims to accelerate drug discovery and advance innovative therapies with significant clinical and commercial potential.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EVGN":"Evogene Ltd."},"translate_title":"Evogene、Systasy和慕尼黑LMU大学医院合作开发中性粒细胞驱动的炎症性疾病疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVGN":0.9},"content_text":"Evogene, Systasy, and LMU University Hospital Munich Partner to Develop Therapies for Neutrophil-Driven Inflammatory Diseases\n    \n\nEvogene Ltd. has announced a collaboration with Systasy Bioscience GmbH and LMU University Hospital Munich to develop novel therapies for neutrophil-derived inflammatory diseases, such as inflammatory bowel disease $(IBD)$. Supported by a pan-European EUREKA grant and involving the Weizmann Institute of Science, the partnership will combine Evogene’s AI-driven ChemPass AI™ platform for small molecule drug discovery, Systasy’s DNA barcoding technology for high-throughput pathway profiling, and LMU’s expertise in stem cell biology and precision diagnostics. The consortium aims to accelerate drug discovery and advance innovative therapies with significant clinical and commercial potential.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN85734) on February 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}